首页> 美国卫生研究院文献>AAPS PharmSciTech >Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2—Evaluation of a method for determining equivalence
【2h】

Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2—Evaluation of a method for determining equivalence

机译:产品质量研究院对药物气雾剂级联冲击器外形的评估:第2部分:确定当量的方法的评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this article is to present the thought process, methods, and interim results of a PQRI Working Group, which was charged with evaluating the chi-square ratio test as a potential method for determining in vitro equivalence of aerodynamic particle size distribution (APSD) profiles obtained from cascade impactor measurements. Because this test was designed with the intention of being used as a tool in regulatory review of drug applications, the capability of the test to detect differences in APSD profiles correctly and consistently was evaluated in a systematic way across a designed space of possible profiles. To establish a “base line,” properties of the test in the simplest case of pairs of identical profiles were studied. Next, the test's performance was studied with pairs of profiles, where some difference was simulated in a systematic way on a single deposition site using realistic product profiles. The results obtained in these studies, which are presented in detail here, suggest that the chi-square ratio test in itself is not sufficient to determine equivalence of particle size distributions. This article, therefore, introduces the proposal to combine the chi-square ratio test with a test for impactor-sized mass based on Population Bioequivalence and describes methods for evaluating discrimination capabilities of the combined test. The approaches and results described in this article elucidate some of the capabilities and limitations of the original chi-square ratio test and provide rationale for development of additional tests capable of comparing APSD profiles of pharmaceutical aerosols.
机译:本文的目的是介绍PQRI工作组的思路,方法和中期结果,该工作组负责评估卡方比检验,作为确定体外空气动力学粒径分布(APSD)的潜在方法。 )级联冲击器测量获得的轮廓。因为设计该测试的目的是用作药物应用监管审查的工具,所以在可能的设计空间范围内,系统地评估了该测试正确且一致地检测APSD配置文件差异的能力。为了建立“基线”,研究了在最简单的一对相同轮廓的情况下测试的性能。接下来,使用成对的轮廓研究了测试的性能,其中使用实际的产品轮廓在单个沉积位置上系统地模拟了一些差异。在这些研究中获得的结果(将在此处详细介绍)表明,卡方比检验本身不足以确定颗粒尺寸分布的等效性。因此,本文介绍了将卡方比检验与基于种群生物等效性的撞击物大小质量检验结合起来的建议,并描述了评估结合检验的鉴别能力的方法。本文中描述的方法和结果阐明了原始卡方比检验的某些功能和局限性,并为开发能够比较药用气溶胶APSD曲线的其他检验提供了依据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号